Global Hematologic Malignancies Market, By Type (Leukaemia, Lymphoma, Myeloma), Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Diagnosis (Blood Tests, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the hematologic malignancies market is anticipated to grow rapidly during the forecast period. As per the Globocan 2020 information sheet, there were an anticipated 19,292,789 new cancer cases identified globally, with about 9,958,133 cancer-related deaths. Furthermore, the International Agency for Research on Cancer (IARC) predicts that by 2040, the worldwide incidence of cancer would have increased to 27.5 million new cases and 16.3 million deaths. Hematological malignancies, often known as haematological cancer, are becoming more common around the world. According to the National Cancer Institute, hematological cancer is the fifth most frequent cancer worldwide and the second leading cause of cancer death in the United States. Researchers estimate the incidence of haematological malignancies to rise even more in the next years, resulting in a greater demand for treatment, which will significantly impact the haematological malignancies market.
Data Bridge Market Research analyses that the hematologic malignancies market was valued at USD 59.45 billion in 2021 and is expected to reach USD 138.99 billion by 2029, registering a CAGR of 11.20% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Cancers of the blood-producing cells, such as lymphoma, leukaemia, and multiple myeloma, are referred to as hematologic malignancies. Platelets, red blood cells (RBCs), and white blood cells (WBCs), all of which arise from hematopoietic stem and progenitor cells in the bone marrow, are responsible for oxygen transport, wound clotting and immune protection. Microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling are all used to diagnose hematologic malignancies.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Leukaemia, Lymphoma, Myeloma), Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Diagnosis (Blood Tests, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (UK), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (US)
|
|
Market Opportunities
|
|
Hematologic Malignancies Market Dynamics
Drivers
- Increasing prevalence of hematological cancer
The rising prevalence of hematological cancer is estimated to enhance the hematologic malignancies market's growth rate. Blood cancer is becoming more common, and people are becoming more aware of the disease's risk at an earlier stage. These are the main drivers driving the market. According to the Leukemia and Lymphoma Society, about one person in the United States is diagnosed with blood cancer every three minutes (LLS). Furthermore, the International Agency for Research on Cancer estimates that 10.1 lakh new cases were diagnosed in 2020, with 7 lakh deaths due to Hematologic Malignancies.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of hematologic malignancies market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Advancement in immunohistochemistry (IHC)
Hematologic malignancies can now be accurately detected by exposing tissue samples to diverse antibodies directed against cell molecules and antigens, thanks to developments in immunohistochemistry (IHC). This in turn, estimated to enhance the market's expansion during the forecast period of 2022-2029.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hematologic malignancies market. Additionally, changing lifestyle of people and rising geriatric population will result in the expansion of hematologic malignancies market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hematologic malignancies market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. The advent of new and more efficient diabetic treatment and monitoring products is estimated to boost the market's growth rate in the future.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the hematologic malignancies market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hematologic malignancies market. Additionally, strict regulatory approvals of cancer therapeutics and lack of awareness among people about different types of cancer will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This hematologic malignancies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hematologic malignancies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Hematologic malignancies market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Hematologic Malignancies Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. The COVID-19 outbreak had touched every element of cancer care and research, as screening and oncology care services were categorized as low-priority services in various nations throughout the world. Furthermore, various local and national-level limitations on the movement of persons and goods imposed by public and private authorities were shown to severely disrupt the pharmaceutical products and ingredients supply chain, hampering the hematologic malignancies market's growth. Also, due to pandemic, the temporary closure of numerous academic institutes and difficulty in delivering post-sales services had resulted in a reduced supply of cancer products to end users.
Recent Development
- In April 2021, U.S. Food and Drug Administration (FDA) had granted orphan drug designation to CA-4948. It is a small-molecular inhibitor that targets an oncogenic isoform of a gene which is mainly expressed in individuals with acute myeloid leukaemia and myelodysplastic syndrome. According to Curis, Inc., Receiving orphan drug classification is a significant step forward in the company's objective to reduce or prevent cancer progression in patients with uncommon hematologic malignancies.
- In February 2021, TG Therapeutics Inc. had announced accelerated approval of U.S. Food and Drug Administration (FDA) for its UKONIQ (umbralisib). It is an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon which is used for treating adult patients suffering from relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL).
Global Hematologic Malignancies Market Scope
The hematologic malignancies market is segmented on the basis of type, therapy, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Leukaemia
- Lymphoma
- Myeloma
Therapy Type
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Tyrosine kinase inhibitors
- Proteasome inhibitor
- B-cell lymphoma-2 protein inhibitor
- Isocitrate dehydrogenase-1 inhibitor
- Hedgehog pathway inhibitor
- Others
Diagnosis
- Blood Tests
- Biopsy
- Imaging Tests
- X-ray
- Magnetic resonance imaging (MRI)
- Positron Emission Tomography (PET)
- Others
Dosage form
- Tablets
- Capsules
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Hematologic Malignancies Market Regional Analysis/Insights
The hematologic malignancies market is analysed and market size insights and trends are provided by country, type, therapy, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Hematologic malignancies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the hematologic malignancies market because of the growing number of research and development activities and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, growing prevalence of blood cancer and rising geriatric population will further influence the market's growth rate in this region
Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and increasing penetration of novel cancer drugs in this region. Also, the development of healthcare infrastructure and increasing disposable income will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Hematologic Malignancies Market Share Analysis
The Hematologic malignancies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hematologic malignancies market.
Some of the major players operating in the hematologic malignancies market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Abbott (US)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (UK)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (US)
SKU-